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Only a few cytogenetic and genetic studies have been performed in gastric cancer patients in young age groups. In the present study
we used the comparative genomic hybridisation (CGH) method to characterise frequent DNA copy number changes in 22 gastric
cancer patients of 45 years or younger and three gastric cancer cell lines established from patients younger than 45 years. Analysis of
DNA copy number changes revealed frequent DNA copy number increases at chromosomes 17q (52%), 19q (68%) and 20q (64%).
To confirm the CGH results and to characterise the amplicon region on the most frequently amplified chromosome, chromosome
19, we carried out fluorescence in situ hybridisation (FISH) analysis and Southern blot analysis. Fluorescence in situ hybridisation with
the bacterial artificial chromosome (BAC) clone mapped to 19q12 indicated a copy number increase in all eight tumour specimens
studied. Southern blot analysis of six tumour specimens and three tumour cell lines, with five probes mapped to the 19q12–13.2
region, suggested cyclin E to be one of the candidate target genes in the 19q region for gastric cancer tumorigenesis. Cyclin E protein
overexpression was verified in tumours with amplification on chromosome 19. Further studies are required to investigate the
biological and clinical significance of 19q amplicon and cyclin E upregulation in gastric cancer of young patients.
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Gastric cancer is the second most frequent cancer worldwide
(Parkin et al, 1999), but in young age groups it is rather
uncommon. Several studies have been published about gastric
cancer in young patients aged 45 years or younger (Kokkola et al,
1996; Maehara et al, 1996; Theuer et al, 1996; 1998; Semba et al,
1998; Rugge et al, 1999; Haruma et al, 2000; Kath et al, 2000).
These studies have suggested differences between clinicopatholo-
gical and histological outcome in gastric cancer in young and
elderly age groups. In young patients, gastric cancer has been
suggested to arise with a more aggressive disease and poorer
prognosis. Histologically the diffuse type of gastric cancer
according to Laure ´n (1965) is suggested to be predominant in
young age groups. Helicobacter pylori infection is assessed to be a
risk factor also for young patients in both histological types.
Numerous cytogenetic and genetic aberrations have been
described in gastric cancer in elderly patients. These include
frequent DNA copy number gains in chromosomes 8q, 17q and
20q and losses in chromosome 4 by comparative genomic
hybridisation (CGH) (Kokkola et al, 1997, 1998; El-Rifai et al,
1998, 2001). Several oncogenes, tumour suppressor genes and
mismatch repair genes are assumed to be associated with the
development and progression of gastric tumours. Two of the most
investigated genes are ERBB2 and TOPO2A making them possible
prognostic markers of gastric cancer (Seregni et al, 2001).
Only a few cytogenetic and genetic investigations have been
reported about gastric cancer in young patients (Maehara et al,
1996; Semba et al, 1998; Haruma et al, 2000; Rugge et al, 2000). So
far no reports of sporadic/nonfamilial gastric cancer have
indicated any specific genetic characteristic arising in young
patients compared to elderly patients. Germline E-cadherin
mutations have been found in patients with familial cases of the
diffuse type gastric cancer (Gayther et al, 1998).
In order to find out whether the genetic changes in younger
patients differ from those in older patients, we studied DNA copy
number changes in gastric cancer of young patients. Using CGH,
we analysed 22 tumour samples of patients aged 45 years or
younger, and three gastric cancer cell lines established from
patients who were younger than 45 years. To verify CGH results
and to characterise the amplicon on the most frequently amplified
chromosome, chromosome 19, we performed fluorescence in situ
hybridisation (FISH) analysis for eight patients and Southern
blotting analysis for six patients as well as for three cell lines
derived from gastric carcinomas of young patients. In addition, we
used immunohistochemical analysis for four patients.
MATERIALS AND METHODS
Cell lines
Three gastric cancer cell lines, TMK-1 (obtained from the
Department of Pathology, Hiroshima University School of
Medicine, Hiroshima, Japan), and MKN-7 and MKN-74 (obtained Revised 9 December 2002; accepted 5 March 2003
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sfrom the Second Department of Pathology, Fukushima Medical
College, Fukushima, Japan) were used in this study (Table 1). Cell
lines were cultured under the recommended conditions. All three
cell lines were established from male subjects, ages between 21 and
39 years. Two cell lines (MKN-7, MKN-74) were histologically
classified as well-differentiated tubular adenocarcinoma and one
cell line (TMK-1) as poorly differentiated adenocarcinoma.
Patients
Archival paraffin-embedded specimens from 24 young gastric
cancer patients were obtained from the Department of Pathology
at the Helsinki University Central Hospital, Finland, the Depart-
ment of Pathology at the Jorvi Hospital, Espoo, Finland, and the
Department of Pathology at the Academic Medical Center,
Amsterdam, Netherlands.
In all, 15 patients had intestinal type of gastric cancer, seven
patients had diffuse type of gastric cancer, and two patients were
diagnosed with mixed type of gastric cancer. The median age of
patients was 39 years (range 18–45 years), and 14 of them were
male patients. Two of the patients had family history (cases 11 and
24) of gastric cancer.
Gastric carcinomas were classified by an experienced patholo-
gist. A distinction was made between the two main histological
subtypes and in early and advanced carcinomas.
Comparative genomic hybridisation (CGH)
For CGH, DNA was extracted from three cell lines, paraffin-
embedded specimens from 22 young gastric cancer patients, and
from the peripheral blood of a healthy male or female (reference
DNA) using standard protocols. Comparative genomic hybridisa-
tion was performed and analysed as described previously (El-Rifai
et al, 1997; Varis et al, 2001).
Nuclei extraction and FISH
The nuclei from the paraffin-embedded tissues were extracted
from the eight patients and two reference samples. Paraffin
sections of 10mm that were very rich in tumour cells were used in
nuclei isolation of tumour samples. As a probe for the interphase
FISH, we used bacterial artificial chromosome (BAC) clone CTC-
525D6 (AC011474; Research Genetics, Huntsville, AL, USA). The
nuclei extraction, FISH and analysis were performed as described
previously (Hemmer et al, 2001), except origin of two reagents,
biotin-14-dATP and Cot-1 DNA, which were purchased from
Gibco BRL (Geithessburg, MD, USA).
Southern blotting
Genomic DNA for Southern blotting was extracted from three cell
lines and the sections of the frozen material of six patient samples
using standard protocols. Southern blotting and hybridisations
were performed by standard laboratory methods (Weterman et al,
1996). The percentage of tumour cells was estimated on an HE-
stained section of the frozen material.
Southern blot analysis was performed using phosphorimager
(Fuji) and AIDA software v.2.41. The signal intensity in the lanes
containing tumour DNA was divided by the intensity obtained for
the corresponding normal DNAs. Both signals were adjusted for
loading differences and background using a b-globin control
probe. The threshold value for amplification was 2.5. If
corresponding DNA from normal tissue was not available (cell
lines and case 23), intensity for normal DNA was based on the
average intensity of signals from all other normal DNAs.
Five cDNA image clones for Southern blotting were obtained
from the RZPD (Deutsches Ressourcenzentrum fu ¨r Genom-
forschung GmbH, Heubnerweg 6, D-14059 Berlin, Germany).
The clones were sequence verified and the corresponding
inserts were isolated using appropriate restriction analysis and
purification prior to labelling. The clones used were IMAGp998-
O145473 (CCNE), IMAGp998B125762 (CEBPA), IMAGp998K066030
(TGFB), IMAGp998O131258 (BCL3) and IMAG p998B152412
(AKT2).
Immunohistochemistry
Immunohistochemistry for cyclin E was performed using the
monoclonal antibody CYE5 (Neomarkers, Fremont, CA, USA) in
1:40 dilution. Briefly, paraffin-embedded specimens were sec-
tioned (4mm), deparaffinised, blocked for endogenous peroxidase
activity by immersion in 0.3% H2O2 in methanol for 20min and
heat treated at 1001C in (pH 9) for 10min. Nonspecific binding
sites were blocked in 5% normal goat serum for 10min following
the incubation for 1h with the primary antibody at room
temperature. The Powervisionþpoly-HRP detection system
(ImmunoVision Technologies, Co, Daly City, CA, USA) was used
to visualise the antibody binding sites with 3,3-diamino-
benzidineþ as a chromogen. Sections were counterstained with
haematoxylin.
RESULTS
Comparative genomic hybridisation
To identify DNA sequence copy number changes in young patients
with gastric cancer, 25 gastric carcinoma patient samples and three
cell lines were included in CGH analysis. A summary of the gains
and losses detected by CGH is shown in Figure 1. Detailed clinical
and karyotypic data are presented in Table 1, which is available as
a supplement on the BJC web site, www.nature.com/bjc/. DNA
copy number changes were more frequent in intestinal cases (13
out of 14 cases, 93%) than in diffuse cases, of which only one of the
six cases was abnormal (17%). DNA copy number changes were
detected in both mixed gastric carcinoma and all three gastric
carcinoma cell lines. The most common changes were gains at
chromosome 19q (17 out of 25, 68%), at chromosome 20q (16 out
of 25, 64%) and at chromosome 17q (13 out of 25, 52%). Losses
were frequent at chromosome 4 (10 out of 25, 40%).
In the group of intestinal carcinomas DNA copy number
increase was frequently observed in chromosomal arms 20q (86%),
17q (71%) and 19q (71%). Frequent losses were seen at 4q (50%)
and 5q (29%). High-level amplifications were present on the q-arm
of chromosome 17, p-arm of chromosome 18, q-arm of chromo-
some 19 and in chromosome 20. In all three cell lines derived from
young patients gains were detected for chromosomes 5, 11, 19 and
20. High-level amplifications were again seen on chromosomes 19
and 20, but also in chromosomes 7 and 11.
Interphase FISH
In order to confirm the results obtained by CGH, eight gastric
cancer cases of the intestinal type (cases 2, 8, 9, 10, 11, 12, 14 and
15) with amplification on chromosome 19 or the 19q arm and two
normal stomach tissues were investigated by FISH using BAC
CTC-525D6, which maps to 19q12, as a probe. This also allows for
specification of copy number changes in the tumours examined.
On average two signals were observed in two normal stomach
tissue preparations. One case (case 10), which showed high-level
amplification on chromosome 19 by CGH, had an average of over
20 copies per nucleus for BAC CTC-525D6. Other samples of
tumor tissue also showed increases in copy numbers for BAC CTC-
525D6 the range being between 2.5 and 5.5 copies per nucleus
(Table 1).
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sTable 1 Clinical characteristics, CHG findings, Southern blotting and FISH results of tumour specimens and cell lines
No. Age/sex Histology Stage CGH results/gains CGH results/losses
Southern blotting
results, amplified
genes (ratio
a)
Interphase FISH
signals (BAC CTC-
525D6)/average
signals/nucleus)
1 42/M Intestinal Advanced 5p, 8q, 17q12-qter, 19cen-q13.2 4, 5q, 6qcen-q22, 9p22-pter — —
2 39/M Intestinal Advanced 11qcen-q14, 19 4 — 2.5
3 41/M Intestinal Advanced 1q21-qter, 5p, 6cen-6p22, 6q16-qter,
7p, 8q, 11q13-pter, 13, 17/17q12–q21.32,
18/18p11.3, 20/20p11.22-pter/20q11.22-qter
1p31.2–p21.2, 2q21-qter, 4p,
4q24-qter, 5qcen-q31,
12q15-q22
——
4 44/F Intestinal Early 1q21-qter, 6p12.2-pter, 7q21.1-pter, 11qcen-q13,
12p, 16q11.2-pter, 17q22-pter/
17qcen-q21.32, 19, 20
3, 4, 9p, 12q15–q22 — —
5 44/M Intestinal Advanced 1q21-q23, 8p12-pter, 9p13-qter, 11q13,
17q, 18p11.3, 19, 20
18q — —
6 45/M Intestinal Advanced 19, 20 No losses — —
7 41/M Intestinal Advanced 1q21-q25, 3q26.2-qter, 6pcen-p22, 11q14-q12,
12, 17/17q, 19, 20q/20q, 22
4, 5q14.2-q23, 18q — —
8 42/M Intestinal Advanced 4p15.3-pter, 5p15.1-pter, Xq24-qter, 7, 8q,
10q, 11qcen-q14, 12p12-pter, 16, 17q, 19,
20q11.2-qter
4q, 6q25.2-p12.2, 13 — 2.7
9 39/M Intestinal Advanced 1q, 7, 8q, 10p, 17q21-qter, 18p,
19, 20
No losses — 3.8
10 43/M Intestinal Advanced 1q, 2q34-qter, 7pter-q21,12q14-q15, 17,
18p, 19/19cen-q13.1, 20q12-qter
4, 5p13-q23.2, 9p24 CCNE (31) 420
11 37/F Intestinal Advanced 1q, 5p15.1-pter, Xq/Xq22-qter, 8q, 9q, 13, 16p,
17cen-q23, 19, 20
No losses AKT2 (4.7) 3.0
12 45/M Intestinal Advanced 11, 12p11.2-p12, 19, 20q11.22-qter No losses No amplification 2.9
13 30/F Intestinal Advanced Normal Normal — —
14 28/M Intestinal Advanced 7p13-pter, 8q, 13q12-q14.11, 17q12–q21.31,
19cen-q13.2, 20q
No losses — 5.5
15 39/M Mixed Advanced 1p31.2-pter, 1q, 2q34-qter, 5p13-pter, 7pter-q31.2/
7p13-21, 8q12-qter,
9q21.12-qter, 11q12.2–q13,
12, 15, 17, 19, 20/20
11q22.3-qter No amplification 2.5
16 42/F Mixed Advanced 16p No losses — —
17 42/F Diffuse Advanced Normal Normal — —
18 39/F Diffuse Advanced Normal Normal — —
19 41/M Diffuse Advanced Normal Normal — —
20 38/M Diffuse Advanced Normal Normal — —
21 39/F Diffuse Advanced 8q, 13, 16p, 19p 8p, 9p, 16q — —
22 18/F Diffuse Advanced Normal Normal — —
23 43/M Diffuse Advanced Sample not available Sample not available CCNE (3) —
24 36/M Intestinal Advanced Sample not available Sample not available No amplification —
25 TMK-1 21/M Poorly differentiated
adenocarcinoma
1q21.2-qter, 5p, Xp21-qter,
10q13-pter/10q, 11q, 14,
19cen-q13.2, 20q
4,6q, 8q13-pter, 12p,
13, 18q21-qter, 21
CEBPA (4.1) —
26 MKN-7 39/M Well differentiated
tubular adenocarcinoma
2p21-pter, 5p, X, 7p/7p15-pter,
8q22-qter78q24.1-qter,
9q32-qter, 11/11q13.5-q14,
14, 17, 18p, 19/19cen-q13.3,
20/20, 21q21-qter
1p32-q21.1, 4q24-pter,
6q15-q23, 8p21-pter,
9q21.32-pter, 10,
12q21.32-pter, 15q21-pter,
18q22-qter
CCNE (11) CEBPA
(4.6) AKT2 (2.9)
—
27 MKN-74 37/M Well differentiated
tubular adenocarcinoma
3q21-qter, 5, X/Xp, 6p12-pter,
7/7pcen-p15.1/7q22.2-q32.1, 11qcen-q21, 11q23.2-qter/
11q24-qter, 12q21.2-pter, 13q32-qter,
14, 15q21-qter, 17, 19, 20, 21q22
1q21-p22, 1q42-qter, 4p14-qter,
6q15-qter, 8q11.21-q21.3,
9q34.11-pter, 18q21-q22.1
BCL3 (3) —
Straight line¼sample not available or no indication for the Southern blotting of FISH.
aThe threshold value for amplification¼2.5.
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To characterise the amplified region on chromosome 19 in more
detail, Southern blot analysis was performed for six gastric cancer
tumours (cases 10, 11, 12, 15, 23 and 24) of which frozen material
was available and five normal controls (cases 10, 11, 12, 15 and 24)
of the same patients. In addition, three gastric cancer cell lines
(MKN-7, MKN-74 and TMK-1) derived from young patients were
analysed. Five cDNA clones that mapped to the 19q12–13.2 region
[CCNE, CEBPA, AKT2, TGFB and BCL3, mentioned in the order of
their location on chromosome 19 (Table 1)] were used as probes.
The highest amplification level was seen for CCNE (cyclin E) in
case no 10 (ratio 31) and cell line MKN-7 (ratio 11). Amplifications
were also detected at a lower level for CEBPA and AKT2.
Amplification of BCL3 was only detected in one case and TFGFB
was not amplified in any of the samples.
Cyclin E expression
Four samples from young gastric cancer patients were immuno-
stained for cyclin E. Two of the cases (cases 17 and 19, Table 1)
without any 19q abnormalities did not show overexpression of
cyclin E (Figure 3), whereas the other two cases (cases 10 and 14,
Table 1) with a 19q amplicon detected by other methods showed
positive staining for cyclin E (Figures 2 and 3).
DISCUSSION
In the present study we used CGH to characterise DNA copy
number changes in young patients with gastric cancer. The most
frequent cytogenetic aberrations were gains seen at 17q (52%), 19q
(68%) and 20q (64%). DNA copy number changes were mostly
detected in intestinal or mixed types of tumour, which is in
agreement with our previous studies of gastric cancer tumours
(Kokkola et al, 1997, 1998). Our study of intestinal type of
tumours, in which the mean age of the patients was 67 years,
showed frequent gains in chromosomes 8q (45%), 17q (41%) and
20q (55%) and losses in chromosomes 4q (32%) and 18q (41%),
whereas no abnormalities were observed for chromosome 19. Our
results of DNA copy number changes in older age group accord
well with the results of the other CGH studies in older gastric
cancer patients (Van Dekken et al, 2001; Wu et al, 2001).
However, some dissimilarities between the published gastric
cancer studies are found, for example, frequency of abnormalities
in chromosome 19. In the study of Van Dekken et al (2001) gain at
19q was involved in 30% of cases in older age group. Still, the
frequency of the 19q gain observed in our present study on young
patients is significantly higher than previously indicated in gastric
cancer.
The most remarkable difference we detected in relatively young
patients compared to previous investigations was the frequency of
1 2 3 4
6789 1 0
13
19 20 21 22 Y
14 15 16 17 18
11 12
5 X
Figure 1 Summary of gains and losses in 22 tumours of young gastric cancer patients and three cell lines. Gains are shown on the right sides of
chromosomes and losses on the left sides. Intestinal tumours, solid lines; mixed tumours, broken lines; diffuse tumours, dotted lines; cell lines, open bars.
High-level amplifications are marked with a thick bar.
Figure 2 Immunohistochemical analysis of cyclin E protein expression in
gastric cancer tumours. (A) Diffuse type of gastric cancer tumour without
19q amplicon, no detection of cyclin E overexpression and (B) Intestinal
type of gastric cancer with 19q amplicon, increased nuclear staining of cyclin
E detected.
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at chromosome 19 in other cancers have been described in
myeloma and plasmacytoma, small cell lung cancer, adrenocortical
tumours (childhood) and pancreatic endocrine tumours (Knuutila
et al, 1998, updated 2002, http://www.helsinki.fi/emg).
To confirm and narrow the target region on chromosome 19q,
we performed FISH and Southern blotting analysis. The FISH
study using a BAC probe which, mapped to 19q12, indicated a
copy number increase in all studied tumour specimens in this
region. One of the most likely candidate genes in this region is
CCNE (cyclin E). Amplification of the cyclin E gene was identified
in one cell line and two tumour specimens by Southern blotting.
Three other genes, CEBPA, BCL3 and AKT2, showed lower
amplification status than cyclin E, and Southern blot did not
show any amplification in the TGFB gene. These facts indicate that
the critical target segment is more probably located in the region
between 19q12 and the centromere than in the 19q13.1–13.2
region. Immunohistochemical analysis of cyclin E protein demon-
strated overexpression of cyclin E in tumours with 19q amplicon,
but not in tumours without 19q abnormalities. Further studies are
needed to investigate whether this region includes other genes, in
addition to cyclin E, critical for gastric cancer development and
progression. On the other hand, coamplification of neighbouring
genes in the target segment, without upregulation, may have
occurred (Varis et al, 2002). Previously a few reports have been
published about findings of cyclin E upregulation in gastric cancer
of older patients (Akama et al, 1995; Sakaguchi et al, 1997; Lin et al,
2000).
Overexpresssion of cyclin E has been suggested to correlate with
the P53 expression, progression of gastric carcinoma and poorer
prognosis (Sakaguchi et al, 1997). Cyclin E has an important role as
a cell cycle regulator. After forming a complex with cdk2 cyclin E
regulates the transition from the G1 phase to the S phase in the cell
cycle and, as such, may play a role in gastric carcinogenesis. In
addition to gastric cancer, amplification and overexpression of
cyclin E have been detected in several other carcinomas, including
oesophageal cancer, ovarian cancer and sarcomas (Akama et al,
1995; Donnellan and Chetty, 1999; Lin et al,2 0 0 0 ) .
In this study slight discrepancies between used methods may
exist, caused by the fact that the probes used in FISH and Southern
blot analysis are not overlapping and thus cover another genomic
region, although all map to the 19q12–13.2 region. The BAC clone
CTC-525D6 is mapped to 19q12, but it does not cover the region of
CCNE. In addition, CGH and FISH were performed on the same
paraffin-embedded material with enriched tumour cells, whereas
frozen material with varying proportions of tumour cells was used
for Southern blot analysis. This fact may mask the presence of
amplifications in Southern blot analysis. Nevertheless, it is
important to underline that high-level amplifications at 19q were
observed by all methods used in this study.
Most of the patients had advanced stage of the tumour and for
this reason we were not able to compare the correlation of
chromosomal aberrations with the stages of the tumours.
The target genes in the other frequently amplified region,
17q12–q21, are well studied. In our previous research in gastric
cancer xenografts and cell lines, amplified and overexpressed
genes detected in this region were the well-known TOPO2A and
ERBB2, and one uncharacterised EST (Varis et al, 2002). TOPO2A
and ERBB2 are considered to be possible target genes in cancer
therapy, especially in breast cancer (Cuello et al, 2001; Harris et al,
2001).
Amplification of 20q has been reported in different kinds of
tumours. Several amplified and overexpressed genes have been
identified on this chromosome, such as BTAK in gastric, breast
and ovarian cancer, MYBL2 and ZNF217 in breast and ovarian
cancer, NABC1 in breast cancer, TGIF2 and PTPN1 in ovarian and
breast cancer, and AIB1 in gastric, ovarian, pancreatic and breast
cancer (Collins et al, 1998; Knuutila et al, 1998; Ghadimi et al,
1999; Forozan et al, 2000; Imoto et al, 2000; Sakakura et al, 2000,
2001; Tanner et al, 2000). In addition to BTAK and AIB1, some of
the other known oncogenes in the 20q region may also be target
genes in gastric cancer.
To conclude, our study revealed frequent DNA copy number
changes in young patients with intestinal and mixed types of
gastric cancer and in gastric cancer cell lines established from
young patients. The most frequently observed abnormalities were
gains and high-level amplifications on chromosomes 17q, 19q and
20q. In addition, we identified one amplified and overexpressed
target gene, cyclin E, in the most frequently amplified target
segment of chromosome 19. Further studies would elucidate the
biological and prognostic role of 19q amplicon and cyclin E
upregulation in young patients with gastric cancer.
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